Estrogen for schizophrenia

Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized and placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138901283739N1

Enrollment

Registered

2010-05-29

Start date

2006-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia, schizotypal and delusional disorders

Interventions

Intervention 1: conjugated estrogen 0.625 mg/Day for four weeks. Intervention 2: Placebo.

Treatment - Drugs

Placebo

conjugated estrogen 0.625 mg/Day for four weeks

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: child-bearing age women with chronic schizophrenia, kept in Behravan institute, Yasuj Exclusion criteria: pregnancy, lactation, concurrent hormonal treatment, abnormal uterus bleeding, positive history of deep vein thrombosis, any serious neurologic disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Schizophrenia symptoms. Timepoint: 4 weeks. Method of measurement: PANSS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Mohammadi

Yasuj University of Medical Sciences

amohammadi@hotmail.com+98 74 1223 0290

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026